Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80638 |
Name | B-cell acute lymphoblastic leukemia |
Definition | An acute lymphocytic leukemia characterized by too many B-cell lymphoblasts (immature white blood cells) in the bone marrow and blood. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
NRAS G13D | Everolimus | B-cell acute lymphoblastic leukemia | no benefit | detail... |
KMT2A rearrange | N/A | B-cell acute lymphoblastic leukemia | not applicable | detail... |
JAK2 rearrange | N/A | B-cell acute lymphoblastic leukemia | not applicable | detail... |
JAK3 rearrange | N/A | B-cell acute lymphoblastic leukemia | not applicable | detail... |
JAK2 mutant | N/A | B-cell acute lymphoblastic leukemia | not applicable | detail... |
JAK3 mutant | N/A | B-cell acute lymphoblastic leukemia | not applicable | detail... |
ABL1 rearrange | N/A | B-cell acute lymphoblastic leukemia | not applicable | detail... |
FGFR1 rearrange | N/A | B-cell acute lymphoblastic leukemia | not applicable | detail... |
FLT3 rearrange | N/A | B-cell acute lymphoblastic leukemia | not applicable | detail... |
CDKN2A H142R | Palbociclib | B-cell acute lymphoblastic leukemia | sensitive | detail... |
TP53 mutant | N/A | B-cell acute lymphoblastic leukemia | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00450944 | Phase I | Combotox | Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT01087294 | Phase I | Anti-CD19 CAR-T cells | Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
NCT01853631 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN) | Recruiting | USA | 0 |
NCT02143414 | Phase II | Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Dasatinib + Prednisone Blinatumomab + Dasatinib Blinatumomab | Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT02311998 | Phase Ib/II | Bosutinib + Inotuzumab ozogamicin | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | Completed | USA | 0 |
NCT02315612 | Phase I | Anti-CD22 CAR T cells | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | Completed | USA | 0 |
NCT02420717 | Phase II | Ruxolitinib Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate Dasatinib Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cytarabine + Leucovorin + Methotrexate | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | Terminated | USA | 0 |
NCT02435849 | Phase II | Tisagenlecleucel | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients | Completed | USA | NOR | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 1 |
NCT02458014 | Phase II | Blinatumomab | Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease | Active, not recruiting | USA | 0 |
NCT02535806 | Phase II | Vincristine Sulfate Bortezomib Pegaspargase Methotrexate Cytarabine Mitoxantrone Prednisone | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | Terminated | USA | 0 |
NCT02650414 | Phase I | Anti-CD22 CAR T cells | CD22 Redirected Autologous T Cells for ALL | Recruiting | USA | 0 |
NCT02730312 | Phase I | Vibecotamab | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | Completed | USA | 0 |
NCT02828358 | Phase II | Cytarabine + Hydrocortisone + Leucovorin + Mercaptopurine + Pegaspargase Cyclophosphamide + Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Azacitidine Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Pegaspargase + Thioguanine + Vincristine sulfate liposome Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Thioguanine | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | Active, not recruiting | USA | CAN | AUS | 1 |
NCT02881086 | Phase III | Rituximab Doxorubicin Cytarabine Mercaptopurine Nelarabine Methotrexate Pegaspargase Cyclophosphamide Vindesine Vincristine Sulfate Daunorubicin Dexamethasone | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | Active, not recruiting | DEU | 0 |
NCT03016377 | Phase Ib/II | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | Recruiting | USA | 0 |
NCT03114865 | Phase Ib/II | Blinatumomab + Dexamethasone | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | Active, not recruiting | USA | 0 |
NCT03123939 | Phase III | Tisagenlecleucel | Phase III B in Acute Lymphoblastic Leukemia | Completed | NOR | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 1 |
NCT03233854 | Phase I | Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells NKTR-255 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT03441061 | Phase II | Inotuzumab ozogamicin | Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease | Recruiting | USA | 0 |
NCT03448393 | Phase I | Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | Recruiting | USA | 0 |
NCT03590171 | Phase II | Bortezomib | International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | Recruiting | SWE | POL | NOR | NLD | ITA | ISR | GBR | FRA | FIN | DNK | CZE | BEL | AUT | AUS | 1 |
NCT03594955 | Phase Ib/II | SAR440234 | First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome | Terminated | USA | FRA | 0 |
NCT03595917 | Phase I | Asciminib + Blinatumomab + Dasatinib + Prednisone | ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML | Recruiting | USA | 0 |
NCT03620058 | Phase I | CART22-65s cells + huCART19 CART22-65s cells | CART22 Alone or in Combination With huCART19 for ALL | Active, not recruiting | USA | 0 |
NCT03677596 | FDA approved | Inotuzumab ozogamicin | A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients | Completed | USA | TUR | POL | HUN | ESP | 3 |
NCT03743246 | Phase Ib/II | Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | Terminated | USA | NLD | ITA | FRA | ESP | DEU | 0 |
NCT03792633 | Phase II | huCART19 | Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL | Completed | USA | 0 |
NCT03833180 | Phase I | VLS-101 | A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies | Completed | USA | 0 |
NCT03876769 | Phase II | Tisagenlecleucel | Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA) | Active, not recruiting | USA | SWE | NOR | NLD | ITA | GBR | FRA | ESP | DNK | CAN | BEL | 0 |
NCT03957915 | Phase I | INA03 | Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (INA03) | Recruiting | FRA | 0 |
NCT04029038 | Phase Ib/II | CD19/CD22 CAR T cells | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma | Withdrawn | USA | 0 |
NCT04029688 | Phase Ib/II | Idasanutlin + Venetoclax Cyclophosphamide + Idasanutlin + Topotecan Cytarabine + Fludarabine + Idasanutlin Cytarabine + Hydrocortisone + Methotrexate Cytarabine Methotrexate Idasanutlin Cyclophosphamide + Idasanutlin | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | Completed | USA | NLD | GBR | FRA | ESP | CAN | 0 |
NCT04049383 | Phase I | Anti-CD19-CD20 CAR T cells | CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T) | Suspended | USA | 0 |
NCT04094311 | Phase III | Tisagenlecleucel | Study of Out of Specification for Tisagenlecleucel | Recruiting | CAN | 1 |
NCT04150497 | Phase I | UCART22 | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | Recruiting | USA | FRA | 0 |
NCT04214886 | Phase I | CD19-CD34 CAR transduced T cells + Cyclophosphamide + Fludarabine | CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT04307576 | Phase III | Imatinib Blinatumomab Inotuzumab ozogamicin | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | Recruiting | SWE | NOR | NLD | LTU | ISL | IRL | GBR | FRA | FIN | EST | DNK | DEU | BEL | 1 |
NCT04506086 | FDA approved | Blinatumomab | Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) | Terminated | USA | 0 |
NCT04509700 | Phase II | Parsaclisib Itacitinib + Parsaclisib | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | Active, not recruiting | USA | TUR | SWE | POL | NOR | ITA | ISR | HUN | GBR | FRA | ESP | DNK | CZE | BEL | AUT | 2 |
NCT04512716 | Phase I | Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells + Iomab-B | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT04521231 | Phase I | Blinatumomab | A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients | Recruiting | USA | TUR | NLD | ITA | FRA | ESP | DEU | CAN | AUT | AUS | 1 |
NCT04530565 | Phase III | Cyclophosphamide + Dasatinib + Dexamethasone + Doxorubicin + Vincristine Sulfate Blinatumomab + Dexamethasone + Ponatinib + Prednisone Blinatumomab + Dasatinib + Dexamethasone + Prednisone Dasatinib Ponatinib Blinatumomab + Dexamethasone + Methotrexate + Ponatinib + Prednisone Blinatumomab + Dasatinib + Dexamethasone + Methotrexate + Prednisone Ponatinib + Prednisone Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Mesna + Methotrexate + Vincristine Sulfate Cytarabine + Methotrexate + Ponatinib Cytarabine + Dasatinib + Methotrexate Cyclophosphamide + Dexamethasone + Doxorubicin + Ponatinib + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Doxorubicin + Methotrexate + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Ponatinib + Vincristine Sulfate Dasatinib + Prednisone | Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults | Recruiting | USA | ISR | 1 |
NCT04546399 | Phase II | Blinatumomab + Methotrexate + Nivolumab Dexamethasone + Pegaspargase + Vincristine Sulfate Blinatumomab + Methotrexate Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Leucovorin + Mercaptopurine + Methotrexate + Thioguanine + Vincristine Sulfate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone Sodium Succinate + Leucovorin + Methotrexate + Nivolumab Blinatumomab + Dexamethasone + Methotrexate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone Sodium Succinate + Methotrexate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone Sodium Succinate + Methotrexate + Nivolumab Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Dexamethasone + Methotrexate + Nivolumab Dexamethasone + Mercaptopurine + Methotrexate + Vincristine Sulfate | A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Suspended | USA | CAN | AUS | 1 |
NCT04556084 | Phase II | Blinatumomab | Blinatumomab Bridging Therapy | Recruiting | USA | 0 |
NCT04681105 | Phase I | Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | Active, not recruiting | USA | 0 |
NCT04690595 | Phase I | BAFFR-CAR T cells | BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL | Recruiting | USA | 0 |
NCT04746209 | Phase II | Blinatumomab | Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT | Recruiting | USA | 0 |
NCT04747912 | Phase II | Dasatinib + Dexamethasone + Inotuzumab ozogamicin + Methotrexate Dasatinib + Dexamethasone + Inotuzumab ozogamicin + Methotrexate + Vincristine Sulfate Dasatinib + Inotuzumab ozogamicin + Methotrexate Dexamethasone + Inotuzumab ozogamicin + Methotrexate + Ponatinib + Vincristine Sulfate | Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) | Recruiting | USA | 0 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04785547 | Phase II | Blinatumomab | ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT | Terminated | SVK | POL | NOR | ITA | FRA | ESP | DNK | CZE | BEL | AUT | 0 |
NCT04845035 | Phase II | Asparaginase + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Leucovorin + Mercaptopurine + Methotrexate + Ponatinib Mercaptopurine + Methotrexate Asparaginase + Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Doxorubicin + Methotrexate + Thioguanine + Vincristine Sulfate Leucovorin + Mercaptopurine + Methotrexate Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Asparaginase + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Thioguanine + Vincristine Sulfate Mercaptopurine + Methotrexate + Ponatinib | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Withdrawn | USA | 0 |
NCT04872790 | Phase I | Dasatinib + Methotrexate + Prednisone + Rituximab + Venetoclax | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | Recruiting | USA | 0 |
NCT04975555 | Phase II | Siltuximab | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | Recruiting | USA | 0 |
NCT04994717 | Phase III | Blinatumomab | Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia | Recruiting | USA | TUR | SWE | ROU | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | 6 |
NCT05016947 | Phase I | Dexamethasone + Inotuzumab ozogamicin + Venetoclax | Venetoclax Plus Inotuzumab for B-ALL | Recruiting | USA | 0 |
NCT05020678 | Phase I | Cyclophosphamide + Fludarabine NKX019 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | Recruiting | USA | AUS | 0 |
NCT05032183 | Phase Ib/II | Cytarabine + Filgrastim + Methotrexate + Rituximab + Tagraxofusp-erzs Cyclophosphamide + Dexamethasone + Mesna + Methotrexate + Rituximab + Tagraxofusp-erzs + Vincristine Sulfate Tagraxofusp-erzs | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Active, not recruiting | USA | 0 |
NCT05049473 | Phase II | Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Hydrocortisone + Ifosfamide + Methotrexate + Prednisone + Rituximab + Vincristine Sulfate + Vindesine | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. | Unknown status | ESP | 0 |
NCT05114837 | Phase Ib/II | CAR19-tTreg Cyclophosphamide + Fludarabine | Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL | Withdrawn | USA | 0 |
NCT05157971 | Phase I | Cyclophosphamide + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate + Pegaspargase + Prednisone + Venetoclax + Vincristine Sulfate | Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT05182385 | Phase Ib/II | Blinatumomab + Venetoclax | Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) | Recruiting | DEU | 0 |
NCT05292664 | Phase I | Azacitidine + Cytarabine + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax Calaspargase pegol-mknl + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax + Vincristine Sulfate Azacitidine + Venetoclax | Venetoclax Basket Trial for High Risk Hematologic Malignancies | Recruiting | USA | 0 |
NCT05303792 | Phase II | Cytarabine + Methotrexate + Methylprednisolone Cyclophosphamide + Dexamethasone + Mesna + Vincristine Sulfate Cytarabine + Inotuzumab ozogamicin + Methotrexate + Methylprednisolone Cyclophosphamide + Dexamethasone + Inotuzumab ozogamicin + Mesna + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Mesna + Rituximab + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Inotuzumab ozogamicin + Mesna + Rituximab + Vincristine Sulfate Cytarabine + Methotrexate + Methylprednisolone + Rituximab Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cytarabine + Inotuzumab ozogamicin + Methotrexate + Methylprednisolone + Rituximab | Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma | Recruiting | USA | 1 |
NCT05310591 | Phase Ib/II | Cyclophosphamide + Fludarabine Nivolumab Tisagenlecleucel | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence (CAPTiRALL) | Recruiting | FRA | 0 |
NCT05348889 | Phase Ib/II | 1A46 | First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies | Recruiting | USA | 0 |
NCT05362773 | Phase I | MGD024 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT05366218 | Phase Ib/II | Tafasitamab-cxix | Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia (Anti-CD19-ALL) | Recruiting | DEU | 0 |
NCT05442515 | Phase Ib/II | CD19/CD22 CAR T cells Cyclophosphamide + Fludarabine | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | Recruiting | USA | 0 |
NCT05453500 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate | Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT05460533 | Phase II | Tisagenlecleucel | A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) | Recruiting | USA | 0 |
NCT05535855 | Phase I | UCD19 CAR T cells | UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 | Recruiting | USA | 0 |
NCT05581030 | Phase I | Calaspargase pegol-mknl + Cyclophosphamide + Dexamethasone + Doxorubicin + Rituximab + Vincristine Sulfate Cytarabine + Methotrexate Calaspargase pegol-mknl + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate | CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Recruiting | USA | 0 |
NCT05645718 | Phase II | Blinatumomab + Cyclophosphamide + Cytarabine + Dexamethasone + Inotuzumab ozogamicin + Mercaptopurine + Methotrexate + Pegfilgrastim + Prednisone + Rituximab + Vincristine Sulfate | Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT05674175 | Phase Ib/II | CART22-65s cells + huCART19 | Co-administration of CART22-65s and huCART19 for B-ALL | Recruiting | USA | 0 |
NCT05779930 | Phase I | Anti-CD19 CAR-T cells | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL | Not yet recruiting | USA | 0 |
NCT05848687 | Phase Ib/II | Bortezomib Dexamethasone Blinatumomab Vorinostat Mercaptopurine Pegaspargase Methotrexate Ziftomenib Mitoxantrone | TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Recruiting | USA | CAN | 0 |
NCT05961696 | Phase I | Mosunetuzumab-axgb | A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | Withdrawn | USA | 0 |
NCT05993949 | Phase I | Dasatinib | Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT06034275 | Phase I | VIP943 | Study of VIP943 in Subjects With Advanced CD123 pos Hematologic Malignancies | Recruiting | USA | 0 |
NCT06080191 | Phase I | CD19-CAR-Lenti_ALLO | Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL | Recruiting | ITA | 0 |
NCT06137118 | Phase Ib/II | TNB-486 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia (SYRUS) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT06144606 | Phase II | Brexucabtagene autoleucel | Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Recruiting | USA | 0 |
NCT06173518 | Phase I | Obecabtagene autoleucel | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | Recruiting | USA | GBR | ESP | 0 |
NCT06287229 | Phase Ib/II | Brexucabtagene autoleucel Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate Blinatumomab + Cyclophosphamide + Dexamethasone + Inotuzumab ozogamicin + Vincristine Sulfate | Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab | Recruiting | USA | 0 |
NCT06287528 | Phase I | 19-28z/IL-18 CAR-T cells | A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) | Recruiting | USA | 0 |
NCT06326463 | Phase I | CD70-CAR-T cells Cyclophosphamide + Fludarabine Mesna | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | Recruiting | USA | 0 |
NCT06395103 | Phase Ib/II | VLS-101 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | Recruiting | USA | ISR | GBR | ESP | BRA | 2 |
NCT06533748 | Phase II | Blinatumomab + Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Inotuzumab ozogamicin + Methotrexate + Vincristine Sulfate Blinatumomab + Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Hydrocortisone + Inotuzumab ozogamicin + Mercaptopurine + Methotrexate + Vincristine Sulfate Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Thioguanine + Vincristine Sulfate | Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma | Not yet recruiting | USA | 0 |
NCT06539338 | Phase I | INT2104 | Safety of INT2104 in Participants Aged 18 Years and Older Who Have B-cell Cancer That Came Back After Prior Treatment (INVISE) | Recruiting | AUS | 0 |